查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747645

全球综合多重诊断市场

Syndromic Multiplex Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 274 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球综合多重诊断市场规模将达 38 亿美元

全球综合多重诊断市场规模预计在2024年为27亿美元，预计到2030年将达到38亿美元，在分析期间（2024-2030年）的复合年增长率为5.6%。呼吸系统疾病是本报告分析的细分市场之一，预计其复合年增长率为4.4%，到分析期结束时将达到16亿美元。胃肠道疾病细分市场在分析期间的复合年增长率预计为7.4%。

美国市场规模估计为 7.364 亿美元，中国市场预计复合年增长率为 8.7%

美国综合多重诊断市场规模预计在2024年达到7.364亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到7.482亿美元，在2024-2030年的分析期内，复合年增长率为8.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.8%和5.5%。在欧洲，预计德国市场的复合年增长率为3.6%。

全球「综合多重诊断」市场—主要趋势与驱动因素摘要

多路復用技术将如何彻底改变疾病的快速检测？

随着病原体的快速进化和对就地检验需求的不断增长，综合征多重诊断已成为临床诊断领域的重大变革。与传统的单检测单病原体模型不同，综合征面板可以同时检测导致特定临床综合征的多种病原体，例如呼吸道感染疾病、胃肠道疾病和中枢神经系统疾病。事实证明，这项技术在急救护理环境中至关重要，因为速度和准确性决定了治疗结果。最近的进展将测试週转时间缩短至一小时以内，有助于及时进行临床决策。 COVID-19 为提高全球对多重检测的认识和采用提供了前所未有的催化剂。 FDA 和 CE 等监管机构已快速核准多重诊断面板，鼓励其扩大临床应用。

多重诊断在儿科护理和免疫力缺乏的患者群体中尤其重要。透过单次检测即可识别合併感染的能力显着减少了不必要的治疗，并有助于对抗抗生素抗药性。新兴市场的企业正在利用微型平台进行创新，以减少设备占用空间并提高其在分散环境中的可近性。值得注意的是，一些企业正在利用人工智慧来增强解读演算法并提供即时决策支援。云端基础的数据与医院资讯系统的整合也是一项重大突破，实现了纵向病患监测和流行病学追踪。随着资源匮乏的医疗保健系统需求的不断增长，人们正在开发具有成本效益的可携式模型，以填补偏远地区的诊断空白。

自动化和人工智慧能否弥补检查能力的差距？

人工智慧和自动化在综合多重诊断中的作用正日益凸显。如今，先进的平台已整合机器人分装、整合式聚合酵素连锁反应热迴圈仪和自动化结果报告功能，显着减少人为干预并最大限度地降低错误率。人工智慧驱动的系统透过解析复杂资料集并更准确地解释模糊结果，增强了病原体识别能力。这些发展显着提高了通量，使得在流行病期间和高容量临床实验室中开展大规模筛检计画成为可能。机器学习还透过分析假阳性和假阴性率随时间的变化来辅助持续的软体最佳化，从而提高演算法的准确性。

与远端医疗的整合进一步提升了综合征检测的效用，使医疗服务提供者能够远端启动和解读检测结果。这尤其推动了行动医疗单位和缺乏实验室专业知识的农村地区诊断的使用案例。同时，综合征系统的可扩展性也吸引了军事和灾难应变组织的关注，他们重视在恶劣环境下的便携性和效率。新兴企业和科技公司正在积极进入该领域，通常与生物技术公司合作，共同开发整合诊断和治疗计划的混合平台。资料安全和互通性如今已成为创新的核心，人们正在探索区块链和分散式帐本技术，以确保共用生态系统中检测结果的完整性。

除了感染疾病以外，还有什么因素推动了人们采用该技术？

虽然综合征多重诊断传统上侧重于感染疾病，但最近的突破已将其应用范围从感染疾病扩展到肿瘤学、药物基因组学和自体免疫疾病等领域。目前，多重检测组已开发用于评估基因标记、肿瘤突变和免疫反应指标，开闢了个人化医疗的新领域。使用多重PCR和次世代定序组进行癌症分析，使临床医生能够在单次检测中提供基于肿瘤生物学的综合治疗。同样，自体免疫检测组可以透过同时检测多种生物标记物，帮助更有效诊断狼疮和类风湿性关节炎等重迭综合征。

在新生儿加护病房(NICU)，多重检测有助于快速诊断性行为感染和代谢紊乱，从而及时介入。在药物基因组学领域，这些检测用于评估患者对药物的独特反应，有助于优化剂量并减少副作用。这在多重用药常见的慢性病管理中尤其重要。人们也越来越关注将综合征诊断与穿戴式健康技术相结合，以创建主动监测系统，这可能会重新定义慢性病的追踪和復发预测。製药公司正在与诊断实验室合作，将多重检测纳入临床试验，以便对患者进行分层并更有效地监测反应。

综合多重诊断市场的成长受到多种因素的推动…

综合征多重诊断市场的成长受到多种因素的驱动，这些因素源自于技术进步、医疗基础设施趋势和不断发展的临床实践。最重要的因素是医院和门诊对快速且全面的诊断解决方案的需求日益增长。随着医疗保健系统优先考虑效率，多重平台正在取代传统的培养和单一病原体检测，以减轻实验室的诊断负担。微流体、实验室晶片平台和整合生物感测器等技术创新正在实现诊断系统的微型化，从而提高其在农村和偏远地区的普及率。感染疾病的激增，加上抗生素抗药性的上升，推动了对能够快速区分病毒和细菌病因的检测的需求。

急诊、ICU 和门诊的最终需求也在成长，尤其关注感染疾病、感染疾病和性行为感染感染。消费者行为也在发生变化，大众对早期诊断和预防性筛检的认识不断提高。政府主导的筛检计划和报销政策，尤其是在北美和欧洲，进一步推动了这一趋势。儿科和老年人群是推动采用的关键人群，因为他们都容易受到疾病快速进展的影响。此外，新兴市场的全球卫生计画正在人道行动和大流行病防范计画中引入多重诊断。最后，领先诊断产品製造商的策略投资以及公共卫生机构和诊断产品开发商之间日益加强的合作，正在加速产品平臺，使市场格局保持强劲和竞争力。

部分

类型（呼吸系统、消化器官系统、中枢神经系统、其他类型）、最终使用者（医院、诊断实验室、其他最终使用者）

受访企业范例（共34家）

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioFire Diagnostics（bioMerieux SA）
  • Bio-Rad Laboratories, Inc.
  • Cepheid（A subsidiary of Danaher）
  • Curetis（A subsidiary of OpGen, Inc.）
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口（成品和原始OEM）来预测其竞争地位的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括人为提高销货成本、盈利下降、供应链重组以及其他微观和宏观市场动态。

全球产业分析师密切关注来自全球顶尖首席经济学家（14,949位）、智库（62家）以及贸易和产业协会（171家）的专家的意见，以评估其对生态系统的影响并应对新的市场现实。我们追踪了来自每个主要国家的专家和经济学家对关税及其对本国影响的看法。

全球产业分析师预计，这场动盪将在未来2-3个月内逐渐平息，新的世界秩序将更加清晰地建立。全球产业分析师正在即时追踪这些事态发展。

2025年4月：谈判阶段

在4月的报告中，我们将探讨关税对全球整体市场的影响，并提供区域市场调整。我们的预测是基于历史数据和不断变化的市场影响因素。

2025年7月：最终关税调整

在各国宣布最终重置后，客户将在 7 月收到免费更新，最终更新将包含明确的关税影响分析。

相互和双边贸易及关税影响分析：

美国<>中国<>墨西哥<>加拿大<>欧盟<>日本<>印度<>其他176个国家

领先的产业经济学家：全球产业分析师知识库追踪了 14,949 位经济学家，其中包括来自民族国家、智库、贸易和产业协会、大型企业以及各领域专家的最具影响力的首席经济学家，他们共用了这场前所未有的全球经济状况模式转移的影响。我们超过 16,491 份报告大多遵循基于里程碑的两阶段发布计划。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP35854

Global Syndromic Multiplex Diagnostics Market to Reach US$3.8 Billion by 2030

The global market for Syndromic Multiplex Diagnostics estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Respiratory Disease, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Gastrointestinal Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$736.4 Million While China is Forecast to Grow at 8.7% CAGR

The Syndromic Multiplex Diagnostics market in the U.S. is estimated at US$736.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$748.2 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global "Syndromic Multiplex Diagnostics" Market - Key Trends & Drivers Summarized

How Is Multiplexing Revolutionizing Rapid Disease Detection?

In an era of rapidly evolving pathogens and increasing demand for point-of-care testing, syndromic multiplex diagnostics has emerged as a transformative force in clinical diagnostics. Unlike traditional one-pathogen-per-test models, syndromic panels enable simultaneous detection of multiple pathogens responsible for a specific clinical syndrome, such as respiratory infections, gastrointestinal diseases, or central nervous system disorders. The technology has proven vital in emergency care settings where speed and accuracy can determine treatment outcomes. Recent advancements have reduced test turnaround times to under an hour, facilitating timely clinical decisions. COVID-19 served as an unprecedented catalyst, heightening global awareness and adoption of multiplex testing. Regulatory bodies like the FDA and CE have fast-tracked approvals for multiplex diagnostic panels, encouraging wider clinical application.

Multiplex diagnostics are particularly critical in pediatric care and immunocompromised patient populations, where co-infections are common and symptoms may be atypical. The ability to identify co-infections through a single test has drastically reduced the number of unnecessary treatments, helping combat antimicrobial resistance. Emerging market players are innovating with miniaturized platforms, reducing device footprint and increasing accessibility in decentralized settings. Notably, companies are leveraging AI to enhance interpretation algorithms and provide real-time decision support. Cloud-based data integration with hospital information systems is another major breakthrough, enabling longitudinal patient monitoring and epidemiological tracking. With growing demand from low-resource healthcare systems, cost-effective portable models are being developed to bridge diagnostic gaps in remote regions.

Can Automation and AI Bridge Laboratory Capacity Gaps?

The role of artificial intelligence and automation in syndromic multiplex diagnostics is gaining considerable momentum. Advanced platforms now incorporate robotic pipetting, integrated thermal cyclers, and automated result reporting, greatly reducing human intervention and minimizing error rates. AI-driven systems enhance pathogen identification by parsing through complex data sets to interpret ambiguous results more accurately. These developments have significantly expanded throughput, making large-scale screening programs feasible during epidemics or in high-volume clinical laboratories. Machine learning is also aiding in continuous software optimization by analyzing false-positive and false-negative rates over time to refine algorithm accuracy.

Telemedicine integration has further propelled the utility of syndromic testing, allowing healthcare providers to initiate and interpret tests remotely. In particular, this has boosted use cases in mobile health units and rural diagnostics where lab specialists are scarce. Meanwhile, the scalability of syndromic systems is attracting attention from military and disaster response organizations, who value portability and efficiency in austere environments. Start-ups and tech companies are entering the space aggressively, often partnering with biotech firms to co-develop hybrid platforms that integrate diagnostics with treatment planning. Data security and interoperability are now central to innovation, with blockchain and decentralized ledgers being explored to ensure test result integrity in shared ecosystems.

What’s Driving Adoption Beyond Infectious Diseases?

While syndromic multiplex diagnostics has traditionally focused on infectious diseases, recent breakthroughs are expanding its use into non-infectious realms such as oncology, pharmacogenomics, and autoimmune disorders. Multiplex panels are now being developed to assess genetic markers, tumor mutations, and immune response indicators, opening up new frontiers in personalized medicine. Cancer profiling using multiplex PCR or next-gen sequencing panels allows clinicians to tailor treatments based on comprehensive tumor biology in a single run. Similarly, autoimmune panels help diagnose overlapping syndromes like lupus and rheumatoid arthritis more effectively by detecting multiple biomarkers simultaneously.

In neonatal intensive care units (NICUs), multiplex testing is helping to rapidly diagnose congenital infections or metabolic disorders, ensuring timely interventions. In the pharmacogenomics sector, these tests are used to evaluate patient-specific responses to drugs, aiding in dose optimization and reducing adverse drug reactions. This is especially pertinent in chronic disease management where polypharmacy is common. There is also a growing interest in combining syndromic diagnostics with wearable health tech to create proactive monitoring systems, which could redefine chronic disease tracking and relapse prediction. Pharmaceutical companies are collaborating with diagnostic labs to integrate multiplex testing into clinical trials to stratify patients and monitor responses more effectively.

The Growth in the Syndromic Multiplex Diagnostics Market Is Driven by Several Factors…

The growth in the syndromic multiplex diagnostics market is driven by several factors rooted in technological advancements, healthcare infrastructure trends, and evolving clinical practices. The most significant driver is the increasing demand for rapid, comprehensive diagnostic solutions in both hospital and outpatient settings. As healthcare systems prioritize efficiency, multiplex platforms are replacing traditional culture and single-pathogen tests, reducing the diagnostic burden on laboratories. Innovations in microfluidics, lab-on-chip platforms, and integrated biosensors have enabled the miniaturization of diagnostic systems, increasing their availability in decentralized and rural locations. The proliferation of infectious diseases-coupled with rising antibiotic resistance-has intensified the need for tests that can distinguish between viral and bacterial etiologies swiftly.

End-use demand from emergency departments, ICUs, and ambulatory clinics continues to rise, with particular emphasis on respiratory, gastrointestinal, and sexually transmitted infections. Consumer behavior is also evolving, with increasing public awareness of early diagnosis and preventive screening. This is further supported by government-led screening programs and reimbursement policies, especially in North America and Europe. Pediatric and geriatric populations-both vulnerable to rapid disease progression-are key demographics driving adoption. Additionally, global health initiatives in emerging markets are deploying multiplex diagnostics in humanitarian and pandemic preparedness programs. Finally, strategic investments by major diagnostic players and rising collaborations between public health agencies and diagnostic developers are accelerating product pipelines, ensuring a robust and competitive market landscape.

SCOPE OF STUDY:

The report analyzes the Syndromic Multiplex Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Respiratory, Gastrointestinal, Central Nervous System, Other Types); End-Use (Hospitals, Diagnostics Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Ayoxxa Biosystems
  • Baebies
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company (BD)
  • Biocartis
  • BioFire Diagnostics (bioMerieux SA)
  • Bio-Rad Laboratories, Inc.
  • Cepheid (A subsidiary of Danaher)
  • Curetis (A subsidiary of OpGen, Inc.)
  • GenMark Diagnostics
  • Hologic, Inc.
  • Roche Diagnostics
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Syndromic Multiplex Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Integration of Syndromic Panels in Emergency Care Propels Market Growth
    • Rising Demand for Rapid, Point-of-Care Testing Accelerates Technology Adoption
    • Increased Incidence of Multi-Pathogen Infections Spurs Adoption of Multiplex Solutions
    • Growing Antimicrobial Resistance Strengthens Business Case for Syndromic Testing
    • Automation and Workflow Efficiency in Labs Drives Syndromic Diagnostic Uptake
    • Regulatory Push for Early Disease Detection Expands Market Opportunities
    • Miniaturization and Portability of Devices Drive Penetration in Remote Settings
    • Hospital Consolidation Trends Throw the Spotlight on Integrated Diagnostic Platforms
    • AI Integration in Diagnostic Decision Support Spurs Innovation in Test Panels
    • Expanding Applications in Veterinary and Food Safety Diagnostics Fuel Market Growth
    • Increased Reimbursement Support Across Developed Markets Drives Adoption
    • Rising Awareness Among Clinicians and Patients Accelerates Utilization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Syndromic Multiplex Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gastrointestinal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Gastrointestinal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Central Nervous System by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Central Nervous System by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Syndromic Multiplex Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Syndromic Multiplex Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Syndromic Multiplex Diagnostics by Type - Respiratory, Gastrointestinal, Central Nervous System and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by Type - Percentage Breakdown of Value Sales for Respiratory, Gastrointestinal, Central Nervous System and Other Types for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Syndromic Multiplex Diagnostics by End-Use - Hospitals, Diagnostics Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Syndromic Multiplex Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION